1. Home
  2. KLTR vs PYXS Comparison

KLTR vs PYXS Comparison

Compare KLTR & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaltura Inc.

KLTR

Kaltura Inc.

HOLD

Current Price

$1.47

Market Cap

160.6M

Sector

Technology

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$2.62

Market Cap

172.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLTR
PYXS
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.6M
172.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
KLTR
PYXS
Price
$1.47
$2.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$3.00
$7.00
AVG Volume (30 Days)
477.0K
543.4K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
61.90
3.03
EPS
N/A
N/A
Revenue
$180,854,000.00
$13,858,000.00
Revenue This Year
$2.96
N/A
Revenue Next Year
$4.96
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
1.20
N/A
52 Week Low
$1.06
$0.97
52 Week High
$2.27
$5.55

Technical Indicators

Market Signals
Indicator
KLTR
PYXS
Relative Strength Index (RSI) 59.77 73.44
Support Level $1.39 $1.28
Resistance Level $1.63 $3.89
Average True Range (ATR) 0.09 0.23
MACD 0.00 0.10
Stochastic Oscillator 72.86 77.31

Price Performance

Historical Comparison
KLTR
PYXS

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: